康惠制药(603139) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥132,118,911.52, representing a year-on-year increase of 9.25%[4] - The net profit attributable to shareholders decreased by 63.01% to ¥2,339,881.00 for the same period[4] - The basic earnings per share for Q3 2022 was ¥0.02, down 71.43% compared to the previous year[6] - Total operating revenue for the first three quarters of 2022 reached ¥375,140,799.38, an increase of 11.96% compared to ¥335,095,860.67 in the same period of 2021[23] - Net profit for the first three quarters of 2022 was ¥16,131,708.24, a decrease of 19.93% from ¥20,141,367.56 in the same period of 2021[24] - The company reported a total comprehensive income of ¥16,131,708.24 for the period, down from ¥20,141,367.56 in the previous year[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,934,892,041.45, an increase of 4.01% from the end of the previous year[6] - As of September 30, 2022, the total assets of the company amounted to RMB 1,934,892,041.45, an increase from RMB 1,860,228,725.79 as of December 31, 2021, reflecting a growth of approximately 3.9%[19] - The company reported a total current liabilities of RMB 378,574,593.81, compared to RMB 318,422,684.80 in the previous year, marking an increase of about 18.9%[19] - The total liabilities of the company amounted to ¥813,525,370.95, an increase from ¥745,202,643.53 in the previous year[21] - The company's total liabilities increased to RMB 378,574,593.81, compared to RMB 318,422,684.80 in the previous year, reflecting an increase of approximately 18.9%[19] Cash Flow - The cash flow from operating activities for the year-to-date increased significantly by 390.29% to ¥46,967,223.22[9] - The net cash flow from operating activities was $46,967,223.22, a significant improvement compared to a net outflow of $16,179,335.15 in the previous period, indicating a positive operational performance[31] - Cash inflow from operating activities totaled ¥437,065,260.94, an increase of 18.93% from ¥367,465,136.03 in the previous year[29] - The cash flow from financing activities generated a net inflow of $68,605,879.86, a decrease from $413,853,902.14 in the previous period, reflecting changes in financing strategies[33] - The cash flow from operating activities showed a positive trend, with cash outflows totaling $390,098,037.72, slightly up from $383,644,471.18, but with improved net cash flow[31] Shareholder Information - The company reported a total of 8,370 common shareholders at the end of the reporting period[11] - The largest shareholder, Shaanxi Kanghui Holdings Co., Ltd., holds 36.75% of the shares, with 10,000,000 shares pledged[11] - Total equity attributable to shareholders reached ¥1,055,552,796.94, compared to ¥1,046,679,305.61 in the previous year[21] Investments and Subsidiaries - The company established a new subsidiary, Shaanxi Kanghui New Material Technology Co., Ltd., with a registered capital of RMB 3 million, in which it holds a 60% stake[14] - The company's long-term equity investments rose to RMB 141,935,560.11 from RMB 129,401,455.17, showing an increase of approximately 9.5%[17] - The company has made significant investments, with cash paid for fixed assets and other long-term assets amounting to $140,156,681.06, down from $281,219,578.50, reflecting a strategic shift in capital expenditures[31] Expenses - Total operating costs for the first three quarters of 2022 were ¥362,893,894.67, up 14.06% from ¥318,161,562.53 in the previous year[23] - Research and development expenses increased to ¥9,833,820.15, representing a rise of 62.36% compared to ¥6,079,978.65 in the previous year[23]